Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Emavusertib for Anemia in Lower-Risk Myelodysplastic Syndromes
2020-003986-20Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emavusertib in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Leipzig University. Primary endpoint: Erythroid response (HI-E) per IWG 2018 criteria. Started Mar 2021; status: completed.
02
Drugs
emavusertib
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic myelomonocytic leukemia (CMML)Atypical chronic myeloid leukemia (aCML)
Beyond the preview
Go deeper on 2020-003986-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003986-20.